DOM-BACLOFEN-TAB 20MG TABLET

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

BACLOFEN

متاح من:

DOMINION PHARMACAL

ATC رمز:

M03BX01

INN (الاسم الدولي):

BACLOFEN

جرعة:

20MG

الشكل الصيدلاني:

TABLET

تركيب:

BACLOFEN 20MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

100/500/1000

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

GABA-DERIVATIVE SKELETAL MUSCLE RELAXANTS

ملخص المنتج:

Active ingredient group (AIG) number: 0113246002; AHFS:

الوضع إذن:

MARKETED

تاريخ الترخيص:

1995-12-31

خصائص المنتج

PRODUCT MONOGRAPH
PR
DOM-BACLOFEN
(Baclofen tablets, USP 10 mg & 20 mg)
Muscle Relaxant / Antispastic Agent
DOMINION PHARMACAL
6111 Royalmount Ave., Suite 100
Montreal, Quebec
H4P 2T4
Date of revision:
February 6, 2013
Control No. 161862
_ _
_Dom-BACLOFEN Product Monograph _
_ _
_Page 2 of 23 _
PRODUCT MONOGRAPH
NAME OF DRUG
Pr
Dom-BACLOFEN
(Baclofen Tablets, USP 10mg & 20mg)
THERAPEUTIC CLASSIFICATION
Muscle Relaxant and Antispastic Agent
ACTION
The precise mechanisms of action of baclofen are not fully known. It
inhibits both monosynaptic
and polysynaptic reflexes at the spinal level, probably by
hyperpolarization of afferent terminals,
although actions at supraspinal sites may also occur and contribute to
its clinical effect. Although
baclofen is an analog of the putative inhibitory neurotransmitter
gamma-aminobutyric acid
(GABA), there is no conclusive evidence that actions on GABA systems
are involved in the
production of its clinical effects.
Peak plasma concentrations of baclofen are achieved within 2 hours and
the plasma half-life is
approximately 2-4 hours.
INDICATIONS
Dom-BACLOFEN is useful for the alleviation of signs and symptoms of
spasticity resulting
from multiple sclerosis.
Dom-BACLOFEN may also be of some value in patients with spinal cord
injuries and other
spinal cord diseases.
_ _
_Dom-BACLOFEN Product Monograph _
_ _
_Page 3 of 23 _
CONTRAINDICATIONS
Hypersensitivity to Dom-BACLOFEN or to any of the excipients.
WARNINGS
ABRUPT DRUG WITHDRAWAL:
Following abrupt withdrawal of baclofen, visual and auditory
hallucinations, convulsions (status
epilepticus), dyskinesia, confusion, psychotic, manic or paranoid
states, anxiety with tachycardia
and sweating, insomnia, and worsening of spasticity have occurred.
Therefore, except for serious
adverse reactions, the dose should be reduced slowly when the drug is
discontinued (over a
period of approximately 1-2 weeks).
For the intrathecal formulation of baclofen, it has been reported that
clinical characteristics of
withdrawal may resemble autonomic dysref